Adam K. Stern Buys 20,000 Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Stock
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Adam K. Stern purchased 20,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were acquired at an average price of $0.80 per share, for a total transaction of $16,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NYSEAMERICAN:MTNB traded down $0.03 during trading on Friday, reaching $0.80. 561,282 shares of the stock were exchanged, compared to its average volume of 1,039,420. Matinas BioPharma Holdings Inc has a 1-year low of $0.32 and a 1-year high of $1.50.
Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Monday, May 13th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01).
Several large investors have recently modified their holdings of the company. IPG Investment Advisors LLC raised its position in Matinas BioPharma by 54.5% in the 1st quarter. IPG Investment Advisors LLC now owns 42,500 shares of the company’s stock valued at $46,000 after buying an additional 15,000 shares during the last quarter. Private Advisor Group LLC raised its position in Matinas BioPharma by 100.4% in the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after buying an additional 24,978 shares during the last quarter. Jane Street Group LLC raised its position in Matinas BioPharma by 190.1% in the 1st quarter. Jane Street Group LLC now owns 41,452 shares of the company’s stock valued at $45,000 after buying an additional 27,165 shares during the last quarter. Northern Trust Corp raised its position in Matinas BioPharma by 18.9% in the 4th quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock valued at $109,000 after buying an additional 29,072 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Matinas BioPharma in the 1st quarter valued at $39,000.
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
See Also: How to invest in a bear market
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.